$PLX
Protalix BioTherapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000155837022017554 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $8.620M $14.18M
YoY Change 0.82% 17.66%
Cost Of Revenue $2.400M $7.074M
YoY Change -23.81% 91.03%
Gross Profit $6.220M $7.109M
YoY Change 15.19% -14.87%
Gross Profit Margin 72.16% 50.12%
Selling, General & Admin $3.100M $2.848M
YoY Change -10.66% -3.59%
% of Gross Profit 49.84% 40.06%
Research & Development $5.620M $7.386M
YoY Change -26.44% 1.43%
% of Gross Profit 90.35% 103.9%
Depreciation & Amortization $280.0K $270.0K
YoY Change 7.69% -6.9%
% of Gross Profit 4.5% 3.8%
Operating Expenses $8.710M $10.23M
YoY Change -21.6% -0.02%
Operating Profit -$2.490M -$3.125M
YoY Change -56.39% 65.78%
Interest Expense -$720.0K -$440.0K
YoY Change -20.88% -80.95%
% of Operating Profit
Other Income/Expense, Net -$442.0K
YoY Change -80.9%
Pretax Income -$3.210M -$3.570M
YoY Change -51.87% -15.0%
Income Tax $530.0K
% Of Pretax Income
Net Earnings -$3.740M -$3.567M
YoY Change -43.93% -15.05%
Net Earnings / Revenue -43.39% -25.15%
Basic Earnings Per Share -$0.07
Diluted Earnings Per Share -$0.07 -$0.07
COMMON SHARES
Basic Shares Outstanding 50.67M 49.75M
Diluted Shares Outstanding 49.50M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.10M $10.70M
YoY Change -56.15% 0.94%
Cash & Equivalents $17.11M $10.72M
Short-Term Investments
Other Short-Term Assets $1.310M $1.736M
YoY Change 1.95% -23.66%
Inventory $16.80M $14.56M
Prepaid Expenses $774.0K
Receivables $4.586M $8.651M
Other Receivables $0.00 $0.00
Total Short-Term Assets $44.88M $45.76M
YoY Change -27.22% -35.75%
LONG-TERM ASSETS
Property, Plant & Equipment $4.553M $4.677M
YoY Change -8.24% -7.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M $1.400M
YoY Change -38.1% -26.32%
Total Long-Term Assets $10.91M $10.95M
YoY Change -9.1% -10.68%
TOTAL ASSETS
Total Short-Term Assets $44.88M $45.76M
Total Long-Term Assets $10.91M $10.95M
Total Assets $55.79M $56.71M
YoY Change -24.27% -32.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.27M $5.600M
YoY Change -25.33% -33.33%
Accrued Expenses $8.008M $1.000M
YoY Change -33.16% -16.67%
Deferred Revenue $13.18M $14.79M
YoY Change 54.13% -2.42%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.43M $34.30M
YoY Change -2.25% -19.79%
LONG-TERM LIABILITIES
Long-Term Debt $28.20M $28.10M
YoY Change 1.08% 1.08%
Other Long-Term Liabilities $5.800M $5.800M
YoY Change -68.82% -54.33%
Total Long-Term Liabilities $34.00M $33.92M
YoY Change -26.93% -16.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.43M $34.30M
Total Long-Term Liabilities $34.00M $33.92M
Total Liabilities $66.43M $68.22M
YoY Change -16.65% -18.07%
SHAREHOLDERS EQUITY
Retained Earnings -$389.9M
YoY Change 3.98%
Common Stock $379.2M
YoY Change 2.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$10.64M -$11.51M
YoY Change
Total Liabilities & Shareholders Equity $55.79M $56.71M
YoY Change -24.27% -32.07%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$3.740M -$3.567M
YoY Change -43.93% -15.05%
Depreciation, Depletion And Amortization $280.0K $270.0K
YoY Change 7.69% -6.9%
Cash From Operating Activities -$2.610M -$9.200M
YoY Change -48.72% 389.36%
INVESTING ACTIVITIES
Capital Expenditures $210.0K $60.00K
YoY Change -53.33% -82.35%
Acquisitions
YoY Change
Other Investing Activities $5.160M $5.970M
YoY Change -86.38% 19.88%
Cash From Investing Activities $4.950M $5.910M
YoY Change -86.78% 27.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.080M 1.520M
YoY Change -200.99% -105.85%
NET CHANGE
Cash From Operating Activities -2.610M -9.200M
Cash From Investing Activities 4.950M 5.910M
Cash From Financing Activities 4.080M 1.520M
Net Change In Cash 6.420M -1.770M
YoY Change -77.32% -92.39%
FREE CASH FLOW
Cash From Operating Activities -$2.610M -$9.200M
Capital Expenditures $210.0K $60.00K
Free Cash Flow -$2.820M -$9.260M
YoY Change -49.1% 317.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1070000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
4161000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
dei Trading Symbol
TradingSymbol
PLX
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07601
dei City Area Code
CityAreaCode
201
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47582733
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43761769
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49498105
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45556647
dei Entity Central Index Key
EntityCentralIndexKey
0001006281
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33357
dei Entity Registrant Name
EntityRegistrantName
PROTALIX BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0643773
dei Entity Address Address Line1
EntityAddressAddressLine1
2 University Plaza
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Hackensack
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Local Phone Number
LocalPhoneNumber
696-9345
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50665598
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10720000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38985000
CY2022Q3 plx Short Term Bank Deposits
ShortTermBankDeposits
10091000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8651000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3442000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1736000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1285000
CY2022Q3 us-gaap Inventory Net
InventoryNet
14562000
CY2021Q4 us-gaap Inventory Net
InventoryNet
17954000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
45760000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
61666000
CY2022Q3 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1418000
CY2021Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
2077000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4677000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4962000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4854000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4960000
CY2022Q3 us-gaap Assets
Assets
56709000
CY2021Q4 us-gaap Assets
Assets
73665000
CY2022Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
5639000
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6986000
CY2022Q3 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
12870000
CY2021Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
16433000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1000000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1207000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
14793000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8550000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
34302000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33176000
CY2022Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
28111000
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
27887000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
11790000
CY2022Q3 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
1779000
CY2021Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2472000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4031000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4376000
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
33921000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
46525000
CY2022Q3 us-gaap Liabilities
Liabilities
68223000
CY2021Q4 us-gaap Liabilities
Liabilities
79701000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-11514000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-6036000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56709000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73665000
us-gaap Revenues
Revenues
39021000
us-gaap Revenues
Revenues
29801000
CY2022Q3 us-gaap Revenues
Revenues
14183000
CY2021Q3 us-gaap Revenues
Revenues
12054000
us-gaap Cost Of Revenue
CostOfRevenue
17195000
us-gaap Cost Of Revenue
CostOfRevenue
13201000
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
7074000
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
3703000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23732000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22093000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7386000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7282000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8613000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9263000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2848000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2954000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10519000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14756000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3125000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1885000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1879000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
6613000
CY2022Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
639000
CY2021Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
2410000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1211000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
403000
CY2022Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
197000
CY2021Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
96000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-668000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6210000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-442000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2314000
us-gaap Other Income
OtherIncome
51000
us-gaap Net Income Loss
NetIncomeLoss
-11187000
us-gaap Net Income Loss
NetIncomeLoss
-20915000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3567000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4199000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47582733
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43761769
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49498105
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45556647
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-27037000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37625000
plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
8575000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-6036000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4075000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
30000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1176000
plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
781000
plx Reacquisition Of Equity Component Of Convertible Notes
ReacquisitionOfEquityComponentOfConvertibleNotes
12019000
plx Equity Component Of Convertible Notes Net Of Transaction Costs
EquityComponentOfConvertibleNotesNetOfTransactionCosts
12027000
us-gaap Net Income Loss
NetIncomeLoss
-20915000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
213000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
592000
plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
954000
plx Stock Issued During Period Value Warrants Exercises
StockIssuedDuringPeriodValueWarrantsExercises
2000
us-gaap Net Income Loss
NetIncomeLoss
-11187000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-11514000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
3841000
CY2021Q3 plx Reacquisition Of Equity Component Of Convertible Notes
ReacquisitionOfEquityComponentOfConvertibleNotes
12019000
CY2021Q3 plx Equity Component Of Convertible Notes Net Of Transaction Costs
EquityComponentOfConvertibleNotesNetOfTransactionCosts
12027000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
344000
CY2021Q3 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
219000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4199000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
213000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-9889000
CY2022Q3 plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
1520000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
298000
CY2022Q3 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
124000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3567000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-11514000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
144000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
us-gaap Profit Loss
ProfitLoss
-11187000
us-gaap Profit Loss
ProfitLoss
-20915000
us-gaap Share Based Compensation
ShareBasedCompensation
1546000
us-gaap Share Based Compensation
ShareBasedCompensation
1957000
us-gaap Depreciation
Depreciation
811000
us-gaap Depreciation
Depreciation
859000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1083000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-118000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
-391000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
100000
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
-6000
plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
75000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
51000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-831000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
224000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2569000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-5547000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
13945000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5692000
plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
16000000
plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
37835000
plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-168000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-3392000
plx Proceeds From Sale Of Short Term Deposits
ProceedsFromSaleOfShortTermDeposits
6000000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1648000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4438000
plx Proceeds From Sale Of Short Term Deposits
ProceedsFromSaleOfShortTermDeposits
20000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
415000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-51000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22389000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5198000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1011000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
53000
plx Increase Decrease In Restricted Deposit
IncreaseDecreaseInRestrictedDeposit
-359000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-427000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
81000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9988000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18515000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
25990000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4086000
plx Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
37625000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4161000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8575000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4163000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16124000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-51000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-34000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-28265000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7623000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38985000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18265000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10720000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10642000
plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
205000
plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
387000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
396000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
309000
plx Debt Conversion Transaction Costs In Connection With Exchange Of Convertible Debt
DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt
774000
us-gaap Interest Paid Net
InterestPaidNet
2198000
us-gaap Interest Paid Net
InterestPaidNet
3288000
plx Interest Received Net
InterestReceivedNet
136000
plx Interest Received Net
InterestReceivedNet
445000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33922624
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33295154
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27962842
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26847081
CY2022Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3664000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3166000
CY2022Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2619000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3262000
CY2022Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8279000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
11526000
CY2022Q3 us-gaap Inventory Net
InventoryNet
14562000
CY2021Q4 us-gaap Inventory Net
InventoryNet
17954000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
144000000

Files In Submission

Name View Source Status
plx-20220930_lab.xml Edgar Link unprocessable
0001558370-22-017554-index-headers.html Edgar Link pending
0001558370-22-017554-index.html Edgar Link pending
0001558370-22-017554.txt Edgar Link pending
0001558370-22-017554-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plx-20220930.xsd Edgar Link pending
plx-20220930x10q.htm Edgar Link pending
plx-20220930x10q005.jpg Edgar Link pending
plx-20220930x10q006.jpg Edgar Link pending
plx-20220930x10q007.jpg Edgar Link pending
plx-20220930xex10d1.htm Edgar Link pending
plx-20220930xex10d2.htm Edgar Link pending
plx-20220930xex31d1.htm Edgar Link pending
plx-20220930xex31d2.htm Edgar Link pending
plx-20220930xex32d1.htm Edgar Link pending
plx-20220930xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
plx-20220930_def.xml Edgar Link unprocessable
plx-20220930_pre.xml Edgar Link unprocessable
plx-20220930_cal.xml Edgar Link unprocessable
plx-20220930x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable